Concepedia

G.K. Abou-Alfa

GA

12

Publications

552

Citations

11

H-Index

2004

Active since

Affiliations

Memorial Sloan Kettering Cancer Center(Current)

Cornell University

Johns Hopkins University

University of Michigan

University College London

G.K. Abou-Alfa is an author at Memorial Sloan Kettering Cancer Center specializing in oncology, medicine, and radiation oncology.

Top concepts

Publications per year

2004–2024

12

Publications

12

Outcome of patients with fibrolamellar hepatocellular carcinoma

Francesco Stipa, Sam S. Yoon, Kui Hin Liau et al. · Cancer · 2006 · 228 citations

A randomized phase III trial of DX-8951f (Exatecan Mesylate; DX) and Gemcitabine (GEM) vs. Gemcitabine alone in advanced pancreatic cancer (APC)

E. M. O' Reilly, G.K. Abou-Alfa, R. Létourneau et al. · Journal of Clinical Oncology · 2004 · 67 citations

, , +16

Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis?

G.K. Abou-Alfa, D. Amadori, Armando Santoro et al. · Journal of Clinical Oncology · 2008 · 58 citations

, , +26

An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202

Arndt Vogel, Vaibhav Sahai, Antoine Hollebecque et al. · ESMO Open · 2024 · 54 citations · Full text

Phase II study of cixutumumab (IMC-A12, NSC742460; C) in hepatocellular carcinoma (HCC).

G.K. Abou-Alfa, B. Gansukh, Jung-Mao Chou et al. · Journal of Clinical Oncology · 2011 · 25 citations

, , +14

Rows per page

1–5 of 12